Vigene Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Vigene Biosciences's estimated annual revenue is currently $2.9M per year.
- Vigene Biosciences's estimated revenue per employee is $77,500
- Vigene Biosciences's total funding is $10.5M.
Employee Data
- Vigene Biosciences has 38 Employees.
- Vigene Biosciences grew their employee count by -33% last year.
Vigene Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO & Founder | Reveal Email/Phone |
2 | VP Finance & Accounting | Reveal Email/Phone |
3 | VP Business Development | Reveal Email/Phone |
4 | Senior Director Process Development | Reveal Email/Phone |
5 | Director Quality | Reveal Email/Phone |
6 | Chief Operation Officer | Reveal Email/Phone |
7 | CMC Project Manager | Reveal Email/Phone |
8 | Manager, viral vector based gene therapy and vaccine application | Reveal Email/Phone |
9 | Molecular Cloning Manager | Reveal Email/Phone |
10 | Upstream Process Development Scientist II | Reveal Email/Phone |
Vigene Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $50.8M | 328 | 3% | N/A | N/A |
What Is Vigene Biosciences?
Vigene Biosciences was founded in 2012 by senior scientists with expertise in the fields of virology and gene therapy. At Vigene, we strive to be the leading supplier of gene delivery technologies with the mission to advance biomedical research and to make gene therapy affordable. We offer both research-grade and cGMP-grade AAV, lentivirus, and adenovirus-based products and custom services. Some of our product offerings include ready-to-ship genome wide human cDNA ORFs on adenoviral or lentiviral vectors, AAV shRNA constructs, pre-made control GFP viruses, AAV biosensors developed in partnership with Janelia Research Campus, AAV alpha-synuclein vectors developed in partnership with The Michael J Fox Foundation, and many others. For more information, visit our websites for research (www.vigenebio.com) or cGMP (www.vigenegmp.com) services. You can also follow us on twitter at @VigeneBio.
keywords:N/A
$10.5M
Total Funding
38
Number of Employees
$2.9M
Revenue (est)
-33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Vigene Biosciences News
Global Lentiviral Vector Manufacturing Market Size GlobeNewswire
Global Viral Vector Manufacturing Market Trajectory & Analytics ... Business Wire
... Gene Therapy (a unit of Catalent Biologics), the Chinese company WuXi Advanced Therapies, Novasep, Vigene Biosciences, and Virovek.
ROCKVILLE, Md., April 29, 2019 /PRNewswire/ -- Vigene Biosciences, Inc ("Vigene") a leading provider of viral vector products and services ...
This is the first raise for the business, which has been profitable and fueled growth organically up to this point.
Other Companies in Rockville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.2M | 38 | -5% | N/A |
#2 | $4.4M | 38 | -12% | N/A |
#3 | $6.7M | 38 | 3% | N/A |
#4 | $2.9M | 38 | -33% | $75.4M |
#5 | $8.4M | 39 | 0% | N/A |